CureDuchenne Partners with Tevard Biosciences for Duchenne Muscular Dystrophy Treatment#United_States#Newport_Beach#CureDuchenne#Duchenne_MD#Tevard_Biosciences
CureDuchenne Partners with Tevard Biosciences for Duchenne Muscular Dystrophy Treatment
CureDuchenne announces a partnership with Tevard Biosciences to enhance suppressor tRNA therapy aimed at treating Duchenne muscular dystrophy through innovative medical advancements.
third-news.com
May 20, 2026 at 5:29 PM
CureDuchenne Partners with Tevard Biosciences for Duchenne Muscular Dystrophy Treatment#United_States#Newport_Beach#CureDuchenne#Duchenne_MD#Tevard_Biosciences
PPMD Invests $400,000 in MyoGene Bio to Advance Gene Editing Research#USA#San_Diego#Duchenne_MD#MyoGene_Bio#PPMD_Venture
PPMD Invests $400,000 in MyoGene Bio to Advance Gene Editing Research
The Parent Project Muscular Dystrophy has secured $400,000 in funding for MyoGene Bio, significantly advancing research on Duchenne muscular dystrophy using gene editing technology.
third-news.com
November 4, 2025 at 4:56 PM
PPMD Invests $400,000 in MyoGene Bio to Advance Gene Editing Research#USA#San_Diego#Duchenne_MD#MyoGene_Bio#PPMD_Venture
MyHealthTeam Unveils myMDteam, a Community for Muscular Dystrophy Patients#United_States#San_Francisco#MyHealthTeam#Muscular_Dystrophy#Duchenne_MD
MyHealthTeam Unveils myMDteam, a Community for Muscular Dystrophy Patients
MyHealthTeam has launched myMDteam, a dedicated online community for those with muscular dystrophy, focusing on support and information sharing among patients and caregivers.
third-news.com
July 30, 2025 at 12:05 PM
MyHealthTeam Unveils myMDteam, a Community for Muscular Dystrophy Patients#United_States#San_Francisco#MyHealthTeam#Muscular_Dystrophy#Duchenne_MD
Avidity Biosciences Gains FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen Aiming at Duchenne Muscular Dystrophy Treatment#United_States#San_Diego#Avidity_Biosciences#Duchenne_MD#Delpacibart_Zotadirsen
Avidity Biosciences Gains FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen Aiming at Duchenne Muscular Dystrophy Treatment
Avidity Biosciences has been awarded Breakthrough Therapy designation by the FDA for delpacibart zotadirsen to treat Duchenne muscular dystrophy, enhancing treatment options for patients.
third-news.com
July 23, 2025 at 1:31 PM
Avidity Biosciences Gains FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen Aiming at Duchenne Muscular Dystrophy Treatment#United_States#San_Diego#Avidity_Biosciences#Duchenne_MD#Delpacibart_Zotadirsen
Second Child's Death Raises Alarms Over Gene Therapy Approval Process by FDA#United_States#Palm_Beach_Gardens#Sarepta_Therapeutics#ELEVIDYS#Duchenne_MD
Second Child's Death Raises Alarms Over Gene Therapy Approval Process by FDA
The tragic deaths of two children linked to Elevidys, a gene therapy for Duchenne muscular dystrophy, highlight serious FDA oversight issues and calls for reform.
third-news.com
June 24, 2025 at 6:37 PM
Second Child's Death Raises Alarms Over Gene Therapy Approval Process by FDA#United_States#Palm_Beach_Gardens#Sarepta_Therapeutics#ELEVIDYS#Duchenne_MD